JFrog stock rises as Cantor Fitzgerald maintains Overweight rating after strong Q2
Director and co-founder of Natera, Inc. (NASDAQ:NTRA), Sheena Jonathan, reported selling shares of common stock on August 8 and August 11, 2025, for a total value of $958059. The transactions come as the diagnostic testing company’s stock shows significant momentum, with a 15.7% return over the past week and a 34.27% gain over the last year. According to InvestingPro analysis, the company’s stock currently appears overvalued.
On August 8, Jonathan sold 3,070 shares of Natera common stock in a series of transactions with prices ranging from $156.36 to $164.59 per share. These sales amounted to $494,698.
On August 11, Jonathan sold 2,120 shares of Natera common stock held by Caraluna 1 Trust and Caraluna 2 Trust, with prices ranging from $149.50 to $156.32 per share. The total value of these sales was $324,853 and $138,508 respectively.
The sales were executed under pre-arranged Rule 10b5-1 trading plans adopted on December 11, 2024, and June 7, 2024. Following these transactions, Sheena Jonathan directly owns 242,252 shares of Natera, Inc.
In other recent news, Natera reported its second-quarter 2025 earnings, showcasing a mixed financial performance. The company achieved a revenue of $546.6 million, surpassing forecasts by nearly 15%, although its earnings per share (EPS) fell short at -$0.74 compared to the expected -$0.62. RBC Capital responded to this performance by raising its price target for Natera to $255 from $251, maintaining an Outperform rating due to the company’s strong performance across all categories. Similarly, Bernstein SocGen Group increased its price target to $205 from $200, acknowledging Natera’s robust revenue results that exceeded consensus estimates by 15%. TD Cowen also adjusted its price target, raising it to $215 from $200, while continuing to recommend a Buy rating on the stock. These adjustments reflect positive sentiments among analysts despite the EPS miss, driven by Natera’s strong revenue growth and optimistic guidance.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.